Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: A pediatric oncology group study

Journal of Clinical Oncology

Volumn 23, Issue 18, 2005, Pages 4031-4038

  Pappo, Alberto S ^a   Devidas, Meenakshi ^a   Jenkins, Jessee ^a   Rao, Bhaskar ^a   Marcus, Robert ^a   Thomas, Patrick ^a   Gebhardt, Mark ^a   Pratt, Charles ^a   Grier, Holcombe E ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; VINCRISTINE; ANTINEOPLASTIC AGENT; PROTECTIVE AGENT;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXFOLIATIVE DERMATITIS; FEMALE; FEVER; GRAM NEGATIVE INFECTION; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HUMAN; INFANT; INFECTION; LEG; LIVER VEIN OBSTRUCTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONRHABDOMYOSARCOMATOUS SOFT TISSUE SARCOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; STAPHYLOCOCCUS INFECTION; STOMATITIS; SURVIVAL RATE; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOCALIZATION; VISUAL DISORDER; VOMITING; MULTIMODALITY CANCER THERAPY; SARCOMA; SOFT TISSUE TUMOR; SURVIVAL;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IFOSFAMIDE; MALE; MESNA; NEOADJUVANT THERAPY; PROTECTIVE AGENTS; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 23044441741     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.209     Document Type: Article

References (31)

1. Ries LAG, Smith MA, Gurney JG, et al: Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD, National Cancer Institute, SEER program publication 99-4649, 1999
2. Spunt SL, Poquette CA, Hurt YS, et al: Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: An analysis of 121 patients treated at St Jude Children's Research Hospital. J Clin Oncol 17:3697-3705, 1999
3. Pratt CB, Pappo AS, Gieser P, et al: Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group study. J Clin Oncol 17:1219-1226, 1999
4. Pappo AS, Rao BN, Jenkins JJ, et al: Metastatic nonrhabdomyosarcomatous soft-tissue sarcomas in children and adolescents: The St. Jude Children's Research Hospital experience. Med Pediatr Oncol 33:76-82, 1999
5. Pratt CB, Maurer HM, Gieser P, et al: Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: A Pediatric Oncology Group study. Med Pediatr Oncol 30:201-209, 1998
6. Blackledge G, Steward WP, Verweij J, et al: Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group. Semin Oncol 19:14-18, 1992
7. Antman KH, Ryan L, Elias A, et al: Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 7:126-131, 1989
8. Bramwell VH, Mouridsen HT, Santoro A, et al: Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23:311-321, 1987
9. Maurer HM, Beltangady M, Gehan EA, et al: The Intergroup Rhabdomyosarcoma Study: I. A final report. Cancer 61:209-220, 1988
10. Chang MN, O'Brien PC: Confidence intervals following group sequential tests. Control Clin Trials 7:18-26, 1986
11. Wodowski K, Hill DA, Pappo AS, et al: A chemosensitive pediatric extraosseous osteosarcoma: Case report and review of the literature. J Pediatr Hematol Oncol 25:73-77, 2003
12. Steward WP, Verweij J, Somers R, et al: Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: Preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group. J Cancer Res Clin Oncol 117:5193-5197, 1991 (suppl 4)
13. Steward WP, Verweij J, Somers R, et al: Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 11:15-21, 1993
14. Santoro A, Tursz T, Mouridsen H, et al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537-1545, 1995
15. Antman K, Crowley J, Balcerzak SP, et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11:1276-1285, 1993
16. Edmonson JH, Ryan LM, Blum RH, et al: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11:1269-1275, 1993
17. Schutte J, Mouridsen HT, Steward W, et al: Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 31:S204-S209, 1993 (suppl 2)
18. Patel SR, Vadhan-Raj S, Papadopolous N, et al: High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies-Dose-response and schedule dependence. J Clin Oncol 15:2378-2384, 1997
19. Steward WP, Verweij J, Somers R, et al: The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: Early results from the EORTC Soft-Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 31:5241-3244, 1993 (suppl 2)
20. Bramwell VH, Anderson D, Charette ML, et al: Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: A meta-analysis and clinical practice guideline. Sarcoma 4:103-112, 2000
21. Spunt SL, Hill DA, Motosue AM, et al: Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhabdomyosarcoma soft tissue sarcoma. J Clin Oncol 20: 3225-3235, 2002
22. Gortzak E, Azzarelli A, Buesa J, et al: A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 37:1096-1103, 2001
23. DeLaney TF, Spiro IJ, Suit HD, et al: Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 56:1117-1127, 2003
24. Eilber FC, Rosen G, Eckardt J, et al: Treatment-induced pathologic necrosis: A predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 19:3203-3209, 2001
25. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens-A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17:150-157, 1999
26. Sawyers CL: Imatinib GIST keeps finding new indications: Successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. J Clin Oncol 20:3568-3569, 2002
27. Dematteo RP, Heinrich MC, El-Rifai WM, et al: Clinical management of gastrointestinal stromal tumors: Before and after STI-571. Hum Pathol 33:466-477, 2002
28. Thall PF, Wathen JK, Bekele BN, et al: Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Stat Med 22:763-780, 2003
29. Rosen G, Forscher C, Lowenbraun S, et al: Synovial sarcoma: Uniform response of metastases to high dose ifosfamide. Cancer 73:2506-2511, 1994
30. Singer S, Baldini EH, Demetri GD, et al: Synovial sarcoma: Prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol 14:1201-1208, 1996
31. Nielsen OS, Judson I, van Hoesel Q, et al: Effect of high-dose ifosfamide in advanced soft tissue sarcomas: A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 36:61-67, 2000